The Pharmaceutical Research Center (PRC) (previously named Investigational Drug Services/IDS) ensuresthe safe and ethical provision of investigational/study drugs to research subjects enrolled in clinical drugtrials within the UWCCC. It ensures that drug research protocols proceed optimally through the University ofWisconsin Hospital and Clinics' (UWHC) medication use system and in accordance with all federal, state,institutional and sponsor regulations: The services are continually refined and expanded to meet theevolving needs of the UWCCC clinical research. While the PRC program at UW/UWHC supports allinvestigators conducting clinical drug research, its relationship with the UWCCC is unique in its level ofcommitment, the breadth and depth of services provided, and expertise in handling biohazardous and genetherapy products. The PRC provides detailed protocol review and feasibility assessment within the confinesof an academic medical center. It ensures full compliance with federal, state, sponsor and institutionalrequirements through activities such as: establishment of drug handlihg/distribution/preparation/destructionprocedures; creation of investigational drug monographs for health care providers; education of health carestaff regarding protocol procedures; creation of preprinted physician orders and prescriptions; drug inventorymanagement and accountability; drug preparation and/or oversight; quality assurance audits; and protocolamendment management. It operates satellite pharmacy locations, optimizing ability to extend clinicalresearch into the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-34
Application #
7491887
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-07-23
Project End
2012-03-31
Budget Start
2007-07-23
Budget End
2008-03-31
Support Year
34
Fiscal Year
2007
Total Cost
$102,806
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Goel, Shreya; Ferreira, Carolina A; Chen, Feng et al. (2018) Activatable Hybrid Nanotheranostics for Tetramodal Imaging and Synergistic Photothermal/Photodynamic Therapy. Adv Mater 30:
Wei, Weijun; Ehlerding, Emily B; Lan, Xiaoli et al. (2018) PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging 45:132-150
Yu, Bo; Wei, Hao; He, Qianjun et al. (2018) Efficient Uptake of 177 Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy. Angew Chem Int Ed Engl 57:218-222
Ehlerding, Emily B; Lacognata, Saige; Jiang, Dawei et al. (2018) Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging 45:123-131
Shea, Michael P; O'Leary, Kathleen A; Wegner, Kyle A et al. (2018) High collagen density augments mTOR-dependent cancer stem cells in ER?+ mammary carcinomas, and increases mTOR-independent lung metastases. Cancer Lett 433:1-9
Ko, Huaising C; Kimple, Randall J (2018) The Resident Individual Development Plan as a Guide for Radiation Oncology Mentorship. Int J Radiat Oncol Biol Phys 101:786-788
McDermott, Andrew J; Tumey, Tyler A; Huang, Mingwei et al. (2018) Inhaled Cryptococcus neoformans elicits allergic airway inflammation independent of Nuclear Factor Kappa B signalling in lung epithelial cells. Immunology 153:513-522
You, Xiaona; Kong, Guangyao; Ranheim, Erik A et al. (2018) Unique dependence on Sos1 in Kras G12D -induced leukemogenesis. Blood 132:2575-2579
Ferreira, Carolina A; Hernandez, Reinier; Yang, Yunan et al. (2018) ImmunoPET of CD146 in a Murine Hindlimb Ischemia Model. Mol Pharm 15:3434-3441
Conklin, Matthew W; Gangnon, Ronald E; Sprague, Brian L et al. (2018) Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ. Cancer Epidemiol Biomarkers Prev 27:138-145

Showing the most recent 10 out of 1528 publications